Výsledky vyhledávání - "Ashish M. Ingle"

A phase I trial of MK-2206 in children with refractory malignancies: A Children's Oncology Group study

Autor: Brenda J. Weigel, Matthew M. Ames, Susan M. Blaney, John P. Perentesis, Maryam Fouladi, Renee M. McGovern, Sarah Leary, Christine L Phillips, Charlotte H. Ahern, Peter J. Houghton, L. Austin Doyle, Ashish M. Ingle, Joel M. Reid

Publikováno v: Pediatric Blood & Cancer. 61:1246-1251

Background We report results of a phase I trial designed to estimate the maximum tolerated dose (MTD), describe dose-limiting toxicities (DLT), and characterize the pharmacokinetic profile of MK-2206, an AKT inhibitor, in children with refractory or

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::429347c13eb959b7f1c4d82b80bc7ec5
https://doi.org/10.1002/pbc.25023

Zobrazit plný text záznamu

Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: A children's oncology group study

Autor: Brenda J. Weigel, Rochelle Bagatell, Peter C. Adamson, Ashish M. Ingle, Stephan D. Voss, Elizabeth Fox, Susan M. Blaney, Robin E. Norris, Charlotte H. Ahern, Anthony R. Little

Publikováno v: Pediatric Blood & Cancer. 61:833-839

Background mTOR inhibitors have activity in pediatric tumor models. A phase I trial of the mTOR inhibitor temsirolimus (TEM) with irinotecan (IRN) and temozolomide (TMZ) was conducted in children with recurrent/refractory solid tumors, including cent

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::321f975a807804d52f93b52e8dffe57a
https://doi.org/10.1002/pbc.24874

Zobrazit plný text záznamu

Phase I Pharmacokinetic and Pharmacodynamic Study of Pazopanib in Children With Soft Tissue Sarcoma and Other Refractory Solid Tumors: A Children's Oncology Group Phase I Consortium Report

Autor: Brenda J. Weigel, Pamela Jo Harris, Charlotte H. Ahern, Timothy P.L. Roberts, Ashish M. Ingle, Joel M. Reid, Sylvain Baruchel, Bing Wu, Julia L. Glade Bender, Alice Lee, Stephan D. Voss, Susan M. Blaney

Publikováno v: Journal of Clinical Oncology. 31:3034-3043

Purpose Pazopanib, an oral multikinase angiogenesis inhibitor, prolongs progression-free survival in adults with soft tissue sarcoma (STS). A phase I pharmacokinetic and pharmacodynamic study of two formulations of pazopanib was performed in children

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6158aaa403f93c137f8b85d8ccefc792
https://doi.org/10.1200/jco.2012.47.0914

Zobrazit plný text záznamu

A pediatric phase 1 trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: A children's oncology group phase 1 consortium study

Autor: Lars M. Wagner, Maryam Fouladi, Trent R. Hummel, Joel M. Reid, Susan M. Blaney, Brenda J. Weigel, Richard J. Gilbertson, Terzah M. Horton, Ashish M. Ingle, Renee M. McGovern, Matthew M. Ames, Charlotte H. Ahern

Publikováno v: Pediatric Blood & Cancer. 60:1452-1457

Purpose We conducted a pediatric phase I study to estimate the maximum tolerated dose (MTD), dose-limiting toxicities (DLT), and pharmacokinetic properties of vorinostat, a histone deacetylase (HDAC) inhibitor, when given in combination with temozolo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b6e98e1c3938489509766faa011475cc
https://doi.org/10.1002/pbc.24541

Zobrazit plný text záznamu

A Phase I Trial and Pharmacokinetic Study of Aflibercept (VEGF Trap) in Children with Refractory Solid Tumors: A Children's Oncology Group Phase I Consortium Report

Autor: Ashish M. Ingle, Joel M. Reid, Darrell J. Yamashiro, Brenda J. Weigel, Alice P. Chen, Julia L. Glade Bender, Susan M. Blaney, Scott C. Borinstein, Julie R. Park, Charlotte H. Ahern, Peter C. Adamson, Sylvain Baruchel

Publikováno v: Clinical Cancer Research. 18:5081-5089

Purpose: Aflibercept is a novel decoy receptor that efficiently neutralizes circulating VEGF. A pediatric phase I trial was conducted to define the dose-limiting toxicities (DLT), maximum tolerated dose (MTD), and pharmacokinetics (PK) of aflibercept

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9bbdd55e3e48c6ad0cc08d6bccd7a5ef
https://doi.org/10.1158/1078-0432.ccr-12-0078

Zobrazit plný text záznamu

A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: A Children's Oncology Group phase I consortium study (ADVL0916)

Autor: Jodi A. Muscal, Susan M. Blaney, Igor Espinoza-Delgado, Matthew M. Ames, Joel M. Reid, Renee M. McGovern, Terzah M. Horton, Charlotte H. Ahern, Patrick A. Thompson, Brenda J. Weigel, Ashish M. Ingle

Publikováno v: Pediatric Blood & Cancer. 60:390-395

Background A pediatric Phase I trial was performed to determine the maximum-tolerated dose, dose-limiting toxicities (DLTs), and pharmacokinetics (PK) of vorinostat and bortezomib, in patients with solid tumors. Procedure Oral vorinostat was administ

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2b3e29bb30e7dd612c2244a25f8852a4
https://doi.org/10.1002/pbc.24271

Zobrazit plný text záznamu

Tolerability and pharmacokinetic profile of a sunitinib powder formulation in pediatric patients with refractory solid tumors: a Children’s Oncology Group study

Autor: Susan M. Blaney, Joel M. Reid, Steven G. DuBois, Charlotte H. Ahern, Sylvain Baruchel, Suzanne Shusterman, Ashish M. Ingle, Percy Ivy, Peter C. Adamson, Julia Glade-Bender

Publikováno v: Cancer Chemotherapy and Pharmacology. 69:1021-1027

Sunitinib is an oral tyrosine kinase inhibitor of VEGF, PDGF, c-KIT, and flt-3 receptors. A pediatric phase I study of sunitinib capsules identified the maximum tolerated dose as 15 mg/m(2)/day. This study was conducted to evaluate sunitinib given as

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::84c752546cd9f54caef2217ff6b1ee19
https://doi.org/10.1007/s00280-011-1798-2

Zobrazit plný text záznamu

Phase 2 clinical trial of intrathecal topotecan in children with refractory leptomeningeal leukemia: A Children's Oncology Group trial (P9962)

Autor: Samara L. Potter, Susan M. Blaney, Ashish M. Ingle, Stacey L. Berg, Peter C. Adamson, Mark Krailo

Publikováno v: Pediatric Blood & Cancer. 58:362-365

We performed a phase 2 study in children with recurrent or refractory leptomeningeal leukemia to determine the objective response rate after treatment with intrathecal (IT) topotecan.Patients received age-adjusted IT topotecan (0.4 mg/dose for patien

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::991bfe045379b858bb20912e8ae75807
https://doi.org/10.1002/pbc.23317

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání